<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: forwardlooking", fill: "#e7feff"},
{source: "1: forwardlooking", target: "1: the Securities and Exchange Commission SEC ", fill: "#e7feff"},
{source: "1: the Securities and Exchange Commission SEC ", target: "1: regulations", fill: "#e7feff"},
{source: "1: forwardlooking", target: "2: statements on", fill: "#89cff0"},
{source: "2: statements on", target: "2: drug development activities", fill: "#89cff0"},
{source: "2: drug development activities", target: "2: operations", fill: "#89cff0"},
{source: "2: operations", target: "2: based on", fill: "#89cff0"},
{source: "2: based on", target: "2: current expectations such as statements", fill: "#89cff0"},
{source: "2: current expectations such as statements", target: "2: milestones with respect", fill: "#89cff0"},
{source: "2: milestones with respect", target: "2: technologies", fill: "#89cff0"},
{source: "2: technologies", target: "2: product candidates", fill: "#89cff0"},
{source: "2: statements on", target: "11: spending during", fill: "#db7093"},
{source: "11: spending during", target: "11: next twelve", fill: "#db7093"},
{source: "11: next twelve", target: "11: clinical programs", fill: "#db7093"},
{source: "11: clinical programs", target: "11: administrative", fill: "#db7093"},
{source: "11: administrative", target: "11: activities", fill: "#db7093"},
{source: "11: spending during", target: "13: difficult", fill: "#fada5e"},
{source: "13: difficult", target: "13: additional funds", fill: "#fada5e"},
{source: "13: additional funds", target: "13: operations", fill: "#fada5e"},
{source: "13: operations", target: "13: currently uncertain about", fill: "#fada5e"},
{source: "13: currently uncertain about", target: "13: therapeutic indications", fill: "#fada5e"},
{source: "13: therapeutic indications", target: "13: will continue", fill: "#fada5e"},
{source: "13: will continue", target: "13: clinically", fill: "#fada5e"},
{source: "13: clinically", target: "13: later stages", fill: "#fada5e"},
{source: "13: later stages", target: "13: clinical program", fill: "#fada5e"},
{source: "13: clinical program", target: "13: successfully", fill: "#fada5e"},
{source: "13: successfully", target: "13: selected therapeutic indication", fill: "#fada5e"},
{source: "13: selected therapeutic indication", target: "13: Contents ", fill: "#fada5e"},
{source: "13: Contents ", target: "13: programs will eventually", fill: "#fada5e"},
{source: "13: programs will eventually", target: "13: financed through", fill: "#fada5e"},
{source: "13: financed through", target: "13: collaboration with", fill: "#fada5e"},
{source: "13: collaboration with", target: "13: funded partner", fill: "#fada5e"},
{source: "13: difficult", target: "16: funds through corporate partnerships", fill: "#aa381e"},
{source: "16: funds through corporate partnerships", target: "16: additional sales", fill: "#aa381e"},
{source: "16: additional sales", target: "16: private offerings as", fill: "#aa381e"},
{source: "16: private offerings as", target: "16: markets allow", fill: "#aa381e"},
{source: "16: markets allow", target: "16: acquisition activities", fill: "#aa381e"},
{source: "16: acquisition activities", target: "16: consolidations", fill: "#aa381e"},
{source: "16: funds through corporate partnerships", target: "17: clinical effort", fill: "#fe6f5e"},
{source: "17: clinical effort", target: "17: future capital requirements depend on", fill: "#fe6f5e"},
{source: "17: future capital requirements depend on", target: "17: regulatory approvals", fill: "#fe6f5e"},
{source: "17: regulatory approvals", target: "17: talabostat", fill: "#fe6f5e"},
{source: "17: talabostat", target: "17: reevaluation", fill: "#fe6f5e"},
{source: "17: reevaluation", target: "17: commercial potential", fill: "#fe6f5e"},
{source: "17: commercial potential", target: "17: developments", fill: "#fe6f5e"},
{source: "17: developments", target: "17: competitive", fill: "#fe6f5e"},
{source: "17: competitive", target: "17: establishment", fill: "#fe6f5e"},
{source: "17: establishment", target: "17: sales force", fill: "#fe6f5e"},
{source: "17: clinical effort", target: "21: human clinical development", fill: "#a2add0"},
{source: "21: human clinical development", target: "21: effectiveness", fill: "#a2add0"},
{source: "21: effectiveness", target: "21: currently undergoing evaluation", fill: "#a2add0"},
{source: "21: currently undergoing evaluation", target: "21: clinical trials", fill: "#a2add0"},
{source: "21: clinical trials", target: "21: certain solid tumors", fill: "#a2add0"},
{source: "21: certain solid tumors", target: "21: hematologic", fill: "#a2add0"},
{source: "21: hematologic", target: "21: malignancies", fill: "#a2add0"},
{source: "21: human clinical development", target: "22: regulatory approval", fill: "#ffef00"},
{source: "22: regulatory approval", target: "22: commercial sale", fill: "#ffef00"},
{source: "22: commercial sale", target: "22: talabostat", fill: "#ffef00"},
{source: "22: talabostat", target: "22: intended therapeutic applications", fill: "#ffef00"},
{source: "22: intended therapeutic applications", target: "22: must demonstrate", fill: "#ffef00"},
{source: "22: must demonstrate", target: "22: carefully controlled", fill: "#ffef00"},
{source: "22: carefully controlled", target: "22: effective", fill: "#ffef00"},
{source: "22: effective", target: "22: proposed therapeutic indications", fill: "#ffef00"},
{source: "22: regulatory approval", target: "33: human clinical development", fill: "#a52a2a"},
{source: "33: human clinical development", target: "33: development", fill: "#a52a2a"},
{source: "33: development", target: "33: effective clinical", fill: "#a52a2a"},
{source: "33: effective clinical", target: "33: which will", fill: "#a52a2a"},
{source: "33: which will", target: "33: therapeutic applications", fill: "#a52a2a"},
{source: "33: therapeutic applications", target: "33: currently undergoing evaluation", fill: "#a52a2a"},
{source: "33: currently undergoing evaluation", target: "33: clinical trials", fill: "#a52a2a"},
{source: "33: clinical trials", target: "33: certain solid tumors", fill: "#a52a2a"},
{source: "33: certain solid tumors", target: "33: hematologic", fill: "#a52a2a"},
{source: "33: hematologic", target: "33: malignancies", fill: "#a52a2a"},
{source: "33: human clinical development", target: "45: talabostat", fill: "#b0e0e6"},
{source: "45: talabostat", target: "45: successful drug candidate", fill: "#b0e0e6"},
{source: "45: successful drug candidate", target: "45: successfully", fill: "#b0e0e6"},
{source: "45: successfully", target: "45: potential drug candidates", fill: "#b0e0e6"},
{source: "45: potential drug candidates", target: "45: adversely affected", fill: "#b0e0e6"},
{source: "45: adversely affected", target: "45: talabostat on", fill: "#b0e0e6"},
{source: "45: talabostat on", target: "45: clinical basis", fill: "#b0e0e6"},
{source: "45: clinical basis", target: "45: evaluate new technology", fill: "#b0e0e6"},
{source: "45: evaluate new technology", target: "45: opportunities", fill: "#b0e0e6"},
{source: "45: opportunities", target: "45: expansive corporate relationships such as mergers", fill: "#b0e0e6"},
{source: "45: expansive corporate relationships such as mergers", target: "45: acquisitions", fill: "#b0e0e6"},
{source: "45: talabostat", target: "55: If Tufts University School of Medicine ", fill: "#df00ff"},
{source: "55: If Tufts University School of Medicine ", target: "55: development", fill: "#df00ff"},
{source: "55: development", target: "55: commercialization", fill: "#df00ff"},
{source: "55: commercialization", target: "55: potential products", fill: "#df00ff"},
{source: "55: potential products", target: "55: license key technology", fill: "#df00ff"},
{source: "55: license key technology", target: "55: talabostat", fill: "#df00ff"},
{source: "55: talabostat", target: "55: product from", fill: "#df00ff"},
{source: "55: product from", target: "55: Tufts University School of Medicine Tufts", fill: "#df00ff"},
{source: "55: If Tufts University School of Medicine ", target: "114: outside contractors may give greater priority", fill: "#c00"},
{source: "114: outside contractors may give greater priority", target: "114: reasons may fail", fill: "#c00"},
{source: "114: reasons may fail", target: "114: manufacture", fill: "#c00"},
{source: "114: manufacture", target: "114: talabostat", fill: "#c00"},
{source: "114: talabostat", target: "114: costeffective", fill: "#c00"},
{source: "114: costeffective", target: "114: timely manner", fill: "#c00"},
{source: "114: outside contractors may give greater priority", target: "START_HERE", fill: "#c00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fibroblast_activation_protein,_alpha">Fibroblast activation protein, alpha</a></td>
      <td>Fibroblast activation protein alpha (FAP-alpha) also known as prolyl endopeptidase FAP is an enzyme that in humans is encoded by the FAP gene.Prolyl endopeptidase FAP is a 170 kDa membrane-bound gelatinase. It was independently identified as a surface glycoprotein recognized by the F19 monoclonal antibody in activated fibroblasts and a Surface Expressed Protease (seprase) in invasive melanoma cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_drugs:_T–Td">List of drugs: T–Td</a></td>
      <td>This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Analysis_of_clinical_trials">Analysis of clinical trials</a></td>
      <td>The analysis of clinical trials involves many related topics including:\n\nthe choice of an estimand (measure of effect size) of interest that is closely linked to the objectives of the trial,\nthe choice and definition of analysis sets,\nthe choice of an appropriate statistical model for the type of data being studied,\nappropriate accounting for the treatment assignment process,\nhandling of missing data,\nhandling of multiple comparisons or endpoints,\naccounting for interim analyses and trial adaptations,\nand appropriate data presentation.One basic guidance document on this topic is the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidance E9.\n\n\n== Choice of analysis set ==\nFailure to include all participants in the analysis may bias the trial results.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>POINT THERAPEUTICS INC      Item 1A <font color="blue">Risk Factors     </font>   Forward-Looking Statements        This  Item  and  other  Items in this report contain “forward-looking”     information as that term is defined in the Private Securities <font color="blue">Litigation </font>    Reform Act of 1995 or by the Securities and Exchange Commission (SEC) in its     rules, <font color="blue">regulations</font> and releases</td>
    </tr>
    <tr>
      <td>This information includes <font color="blue">statements on</font> the     prospects for our <font color="blue">drug <font color="blue">development</font> <font color="blue">activities</font></font> and results of <font color="blue">operations</font>     <font color="blue">based on</font> our current <font color="blue">expectations</font>, such as statements regarding certain     <font color="blue">milestones with respect</font> to our <font color="blue">technologies</font> and <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>All     statements, other <font color="blue">than statements</font> of <font color="blue">historical facts</font>, included in this     report regarding our strategy, future <font color="blue">operations</font>, future financial position,     future  revenues,  projected costs, prospects, plans and <font color="blue">objectives</font> of     <font color="blue">management</font>  are  forward-looking  statements</td>
    </tr>
    <tr>
      <td>The words “anticipates,”     “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,”     “will,”  “would”  and  similar  <font color="blue">expressions</font>  are  intended to identify     forward-looking statements, although not all forward-looking statements     contain these identifying words</td>
    </tr>
    <tr>
      <td>We may not actually achieve the plans,     intentions or <font color="blue">expectations</font> disclosed in our forward-looking statements and     you should not place <font color="blue">undue reliance on</font> our forward-looking statements</td>
    </tr>
    <tr>
      <td>Actual results or <font color="blue">events could <font color="blue">differ <font color="blue">materially</font></font> from</font> the plans, intentions     and <font color="blue">expectations</font> disclosed in the forward-looking statements we make</td>
    </tr>
    <tr>
      <td>We     have included <font color="blue">important factors</font> in the <font color="blue">cautionary statements</font> included in     this Report on Form 10-K, particularly under the heading “Risk Factors”,     that we believe could cause actual results or events to <font color="blue">differ <font color="blue">materially</font></font>     from  the forward-looking statements that we make</td>
    </tr>
    <tr>
      <td>Our forward-looking     statements do not reflect the <font color="blue">potential impact</font> of any <font color="blue">future <font color="blue">acquisitions</font></font>,     mergers, dispositions, <font color="blue">joint ventures</font> or <font color="blue">investments</font> we may make</td>
    </tr>
    <tr>
      <td>We do not     assume any <font color="blue">obligation</font> to update any forward-looking statements</td>
    </tr>
    <tr>
      <td>If we fail to obtain the <font color="blue">capital <font color="blue">necessary</font></font> to fund our <font color="blue">operations</font>, we will     be unable to <font color="blue">successfully</font> develop or <font color="blue">commercialize</font> <font color="blue">talabostat</font>        As  of  <font color="blue">December </font>31,  2005,  we  had  a  <font color="blue">cash balance</font> of <font color="blue">approximately</font>     dlra37dtta6 million</td>
    </tr>
    <tr>
      <td>We currently anticipate <font color="blue">spending during</font> the <font color="blue">next twelve</font>     months an average of at least dlra7dtta5—dlra8dtta0 million per quarter to fund our     preclinical and <font color="blue"><font color="blue">clinical program</font>s</font> and related general and <font color="blue">administrative</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our current <font color="blue">cash balance</font> is expected to be sufficient to allow     us to maintain our current and planned <font color="blue">operations</font> into the first half of     2007</td>
    </tr>
    <tr>
      <td>It is <font color="blue">difficult</font> to estimate at this time the <font color="blue"><font color="blue">additional</font> funds</font> required     to  finance  our  <font color="blue">operations</font>  as  we are <font color="blue">currently uncertain about</font> the     <font color="blue"><font color="blue">therapeutic</font> <font color="blue"><font color="blue">indication</font>s</font></font> that we <font color="blue">will continue</font> to <font color="blue">clinically</font> develop into     <font color="blue">later stages</font>, the extent of the <font color="blue">clinical program</font> required to <font color="blue">successfully</font>     develop a <font color="blue">selected <font color="blue">therapeutic</font> <font color="blue">indication</font></font>, and if any of these                                           15     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font><font color="blue">programs will eventually</font> be <font color="blue">financed through</font> a <font color="blue"><font color="blue">collaboration</font> with</font> a better     <font color="blue">funded partner</font></td>
    </tr>
    <tr>
      <td>Also, we do not know <font color="blue">whether <font color="blue">additional</font> funding will</font> be     available when needed, or that, if available, we will be able to obtain     <font color="blue">funding on</font> satisfactory terms</td>
    </tr>
    <tr>
      <td>We have incurred <font color="blue">approximately</font> dlra71dtta7 million     of  <font color="blue">expenses since inception through</font> <font color="blue">December </font>31, 2005, and expect our     <font color="blue">capital outlays</font> and operating <font color="blue">expenditures</font> to <font color="blue">increase over</font> the <font color="blue">next several</font>     years as we expand our <font color="blue">infrastructure</font> and clinical and <font color="blue">preclinical trial</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We  may raise these <font color="blue">funds through corporate partnerships</font>,     <font color="blue"><font color="blue">additional</font> sales</font> of securities in both public and <font color="blue">private offerings as</font> the     <font color="blue">markets allow</font>, and merger and acquisition <font color="blue">activities</font> and <font color="blue">consolidations</font></td>
    </tr>
    <tr>
      <td>In addition to the progress of our preclinical and <font color="blue">clinical effort</font>, our     <font color="blue">future <font color="blue">capital <font color="blue">requirements</font></font> <font color="blue">depend on</font></font> many other factors, including: the     cost  and  timing of <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> of <font color="blue">talabostat</font>, technological     advances, the <font color="blue">reevaluation</font> of the <font color="blue">commercial potential</font> of <font color="blue">talabostat</font> in     light of <font color="blue"><font color="blue">development</font>s</font> in our industry or market, the status of <font color="blue">competitive</font>     products and the <font color="blue">establishment</font> of a <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unexpected </font>events or other     <font color="blue">factors beyond</font> our <font color="blue">control could also impact</font> our <font color="blue">capital <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">relinquish rights</font> to our <font color="blue">technologies</font> or <font color="blue">talabostat</font>,     or <font color="blue">grant licenses on terms</font> that are not favorable to us, in order to raise     <font color="blue"><font color="blue">additional</font> funds</font> through alliance, joint venture and <font color="blue">licensing arrangements</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we will be required to delay, reduce     the  scope of or <font color="blue">eliminate one</font> or more of our preclinical and clinical     programs</td>
    </tr>
    <tr>
      <td>Our lead <font color="blue">product candidate</font>, <font color="blue">talabostat</font>, is in <font color="blue">human clinical <font color="blue">development</font></font>,     and its safety and <font color="blue"><font color="blue">effective</font>ness</font> are still being determined        Our lead <font color="blue">product candidate</font>, <font color="blue">talabostat</font>, is <font color="blue">currently undergoing evaluation</font>     in <font color="blue">clinical trials</font> for the treatment of <font color="blue">certain solid tumors</font> and <font color="blue">hematologic</font>     <font color="blue">malignancies</font></td>
    </tr>
    <tr>
      <td>To obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">commercial sale</font> of     <font color="blue">talabostat</font> for its <font color="blue">intended <font color="blue">therapeutic</font> <font color="blue"><font color="blue">application</font>s</font></font>, we <font color="blue">must demonstrate</font> in     <font color="blue">carefully controlled</font> and well-designed <font color="blue">clinical trials</font> that <font color="blue">talabostat</font> is     safe and <font color="blue">effective</font> in humans for the proposed <font color="blue"><font color="blue">therapeutic</font> <font color="blue"><font color="blue">indication</font>s</font></font></td>
    </tr>
    <tr>
      <td>In     addition to <font color="blue">animal safety studies</font>, we have conducted Phase 1 human clinical     safety studies, both in single and multiple doses, which have <font color="blue">provided us</font>     <font color="blue">sufficient safety</font> information to select <font color="blue">dose ranges</font> for our Phase 1 human     <font color="blue">clinical dose finding studies</font></td>
    </tr>
    <tr>
      <td><font color="blue">These Phase </font>1 dose finding studies have, in     turn, <font color="blue">provided us</font> safety and <font color="blue"><font color="blue">effective</font>ness</font> information to select doses for     our  Phase  2  human  <font color="blue">clinical studies which</font> are <font color="blue">evaluating safety</font> and     <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">talabostat</font> in <font color="blue">larger cohort groups</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also recently</font>     <font color="blue">commenced two</font> Phase 3 <font color="blue">human clinical studies</font> in which we are evaluating     <font color="blue">talabostat</font> in <font color="blue">placebo controlled studies</font></td>
    </tr>
    <tr>
      <td>Although with the <font color="blue">completion</font> of     each of our <font color="blue">human clinical studies</font> we are learning more about the safety     profile of <font color="blue">talabostat</font>, we <font color="blue">cannot yet predict whether subjects</font> in clinical     <font color="blue">trials will suffer</font> unacceptable <font color="blue">health consequences</font> related to <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>In addition, success in <font color="blue">preclinical testing</font> and early <font color="blue">clinical trials</font> do not     <font color="blue">necessarily predict final</font> results</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">bio<font color="blue">technology</font> companies</font> have     suffered  <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue">clinical trials</font>, even after     promising results in earlier <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">clinical trials</font> may be     suspended  at any time if the FDA or we believe that the <font color="blue">participating</font>     subjects are exposed to unacceptable health risks</td>
    </tr>
    <tr>
      <td>In addition, we cannot     yet predict whether <font color="blue">talabostat</font> will be <font color="blue">effective</font> treating the <font color="blue">therapeutic</font>     <font color="blue"><font color="blue">application</font>s</font> for which the <font color="blue">human clinical studies</font> we are conducting have     been  designed  or that physicians or the FDA will consider <font color="blue">talabostat</font>     <font color="blue">effective</font> for such <font color="blue">therapeutic</font> <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, even if <font color="blue">talabostat</font>     is shown to be <font color="blue">effective</font> in our <font color="blue">clinical trials</font>, we <font color="blue">cannot predict whether</font>     the FDA will determine that the <font color="blue">therapeutic</font> benefits of <font color="blue">talabostat</font> outweigh     any perceived <font color="blue">adverse effects</font> of the drug</td>
    </tr>
    <tr>
      <td>If <font color="blue">talabostat</font> is not safe or     <font color="blue">effective</font>, or is perceived as not being safe or <font color="blue">effective</font> by the FDA or     physicians, our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and     <font color="blue">prospects will</font> be harmed</td>
    </tr>
    <tr>
      <td>Our lead <font color="blue">product candidate</font>, <font color="blue">talabostat</font>, is in <font color="blue">human clinical <font color="blue">development</font></font>,     and  we  may  not be able to design or implement an <font color="blue">effective</font> clinical     <font color="blue">development</font> plan <font color="blue">which will</font> result in timely FDA approval for the selected     <font color="blue">therapeutic</font> <font color="blue"><font color="blue">application</font>s</font>        Our lead <font color="blue">product candidate</font>, <font color="blue">talabostat</font>, is <font color="blue">currently undergoing evaluation</font>     in <font color="blue">clinical trials</font> for the treatment of <font color="blue">certain solid tumors</font> and <font color="blue">hematologic</font>     <font color="blue">malignancies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font><font color="blue">clinical trials</font> is a lengthy and <font color="blue">highly uncertain</font>     process</td>
    </tr>
    <tr>
      <td>The length of time to complete <font color="blue">clinical trials</font> varies according to     the type, complexity, novelty and                                           16     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font><font color="blue">intended use</font> of the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We may not have designed our clinical     trials  in  a  way that results in their fastest <font color="blue">completion</font> because of     <font color="blue">unforeseen safety</font> or <font color="blue"><font color="blue">effective</font>ness</font> issues</td>
    </tr>
    <tr>
      <td>Our trials may take longer to     complete  than we anticipate because of a <font color="blue">slower than</font> expected rate of     eligible subject <font color="blue">recruitment</font> in the trials</td>
    </tr>
    <tr>
      <td>If our <font color="blue">clinical trials</font> take     <font color="blue">longer than</font> we expect, we may have <font color="blue">greater expenses than</font> we project and may     have a more <font color="blue">difficult</font> time <font color="blue">raising <font color="blue">additional</font> capital</font> to <font color="blue">fund future</font> or even     existing <font color="blue">capital <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>Even if we are able to conduct our <font color="blue">clinical trials</font> in a <font color="blue">timely manner</font>, other     factors related to the conduct of the <font color="blue">trials could still <font color="blue">adversely affect</font></font>     our chances of obtaining FDA approval</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">adequately</font>     follow or evaluate the subjects of the <font color="blue">clinical trials</font> after their treatment     to establish a positive <font color="blue">therapeutic</font> effect</td>
    </tr>
    <tr>
      <td>We may not be able to maintain a     database  of  sufficient  integrity  to <font color="blue">track safety</font> and <font color="blue"><font color="blue">effective</font>ness</font>     information  of  <font color="blue">treated subjects</font> that <font color="blue">would withstand appropriate</font> FDA     scrutiny</td>
    </tr>
    <tr>
      <td>We, or our chosen vendors, may fail to comply with FDA <font color="blue">regulations</font>     for good <font color="blue">clinical practices</font></td>
    </tr>
    <tr>
      <td>If we obtain FDA approval for one or more <font color="blue"><font color="blue">therapeutic</font> <font color="blue"><font color="blue">indication</font>s</font></font>, we may     then elect to perform <font color="blue">further clinical studies intended</font> to broaden the     <font color="blue">labeling <font color="blue"><font color="blue">indication</font>s</font></font></td>
    </tr>
    <tr>
      <td>If <font color="blue">such studies</font> do not <font color="blue">support expanding</font> the labeling     <font color="blue"><font color="blue">indication</font>s</font>,  our  ability to promote and <font color="blue">market such <font color="blue">products will</font></font> be     limited</td>
    </tr>
    <tr>
      <td>If <font color="blue">talabostat</font> is not a <font color="blue">successful drug candidate</font>, and we are unable to     obtain or <font color="blue">successfully</font> develop other <font color="blue">potential drug <font color="blue">candidates</font></font>, we may be     <font color="blue"><font color="blue">adversely affect</font>ed</font>        In  addition  to  our  substantial  efforts developing <font color="blue">talabostat</font> on a     preclinical and <font color="blue">clinical basis</font>, we from time to time <font color="blue">evaluate new <font color="blue">technology</font></font>     <font color="blue">opportunities</font>  to  broaden our portfolio of <font color="blue">potential drug <font color="blue">candidates</font></font>,     including in-licensing <font color="blue">opportunities</font>, <font color="blue">collaboration</font> arrangements as well as     more expansive corporate <font color="blue">relationships</font>, such as mergers and <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>However, we may not be able to consummate a <font color="blue">transaction</font> to broaden our     portfolio of <font color="blue">potential drug <font color="blue">candidates</font></font> on terms satisfactory to us</td>
    </tr>
    <tr>
      <td>If     <font color="blue">talabostat</font> is not ultimately a <font color="blue">successful drug candidate</font> and we cannot     obtain  other  <font color="blue">potential drug <font color="blue">candidates</font></font> through one or more strategic     <font color="blue">transaction</font>s, our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     and <font color="blue">prospects will</font> be harmed</td>
    </tr>
    <tr>
      <td>We have had a history of losses, and expect to continue to <font color="blue">incur losses</font> and     may not achieve or maintain <font color="blue">profitability</font>        As of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra62dtta4 million</td>
    </tr>
    <tr>
      <td>The  extent  of  our  future  losses and the timing of     <font color="blue">profitability</font> are <font color="blue">highly uncertain</font>, and we may never achieve profitable     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have not had any products that have generated any sales     revenue, and we <font color="blue">likely will</font> not until <font color="blue">talabostat</font> or any other of our product     <font color="blue"><font color="blue">candidates</font> become <font color="blue">commercially</font> available</font>, if ever</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur losses</font>     <font color="blue">at least until</font> we begin <font color="blue">commercial sale</font>s of our <font color="blue">first approved product</font>, if     any</td>
    </tr>
    <tr>
      <td>We expect that our operating <font color="blue">expenses will increase</font> and <font color="blue">accelerate as</font>     our preclinical, clinical and support <font color="blue">operations</font> expand, even if we succeed     in  developing one or more <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve     <font color="blue">product revenue</font> and <font color="blue">profitability</font> is <font color="blue">dependent on</font> our <font color="blue">capability</font>, alone or     <font color="blue">with partners</font>, to <font color="blue">successfully</font> complete the <font color="blue">development</font> of <font color="blue">talabostat</font>,     conduct  clinical  trials,  obtain <font color="blue">necessary</font> <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>, and     <font color="blue">manufacture</font>, distribute, market and sell <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide</font>     assurance that we will generate <font color="blue">product revenue</font>s or achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">If Tufts University School of Medicine </font>terminates our license, we could     experience  delays  or  be  unable  to  complete  the  <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue">potential products</font>        We <font color="blue">license key <font color="blue">technology</font></font> including the rights to <font color="blue">talabostat</font>, our lead     product, from Tufts University School of Medicine (“Tufts”)</td>
    </tr>
    <tr>
      <td>The underlying     licenses for this <font color="blue"><font color="blue">technology</font> terminate on</font> the later of the date of the     last-to-expire patents, or 15 years from the date of initial <font color="blue">commercial sale</font>     of the <font color="blue">licensed product</font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of these licenses prior to or upon     expiration  of  the  term  could  force us to delay or <font color="blue">discontinue</font> our     <font color="blue">development</font> and <font color="blue">commercialization</font> programs</td>
    </tr>
    <tr>
      <td>Pursuant to the terms of the     license, Tufts has the right to terminate the <font color="blue">license prior</font> to expiration of     the term upon a material breach of the <font color="blue">license by us</font>, our ceasing to do     business or <font color="blue">becoming insolvent</font>, or our failure to sell a <font color="blue">licensed product</font> in     the  US  market  by May 2009</td>
    </tr>
    <tr>
      <td>If we do not meet our <font color="blue">current clinical</font>     <font color="blue">development</font>, <font color="blue">regulatory</font> and <font color="blue">commercialization</font> milestones prior to May 2009,     it is possible that Tufts could seek to terminate or modify the terms of the     license in a way <font color="blue">which could</font> have a material                                           17     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>adverse effect on us</td>
    </tr>
    <tr>
      <td>We have no assurance that we would be able to license     <font color="blue">substitute <font color="blue">technology</font></font> in the future</td>
    </tr>
    <tr>
      <td>Our inability to do so <font color="blue">could impair</font> our     ability to conduct our business because we may lack the <font color="blue">technology</font>, the     <font color="blue"><font color="blue">necessary</font> rights</font> to such <font color="blue">technology</font>, or the finances required, in each case,     to develop and <font color="blue">commercialize</font> our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for <font color="blue">talabostat</font> in a <font color="blue">timely manner</font>,     our operating results and business may be <font color="blue"><font color="blue">adversely affect</font>ed</font>        We must obtain <font color="blue"><font color="blue">regulatory</font> approval</font> before marketing or selling <font color="blue">talabostat</font> in     any <font color="blue">major world <font color="blue">pharmaceutical</font> market</font> for any <font color="blue">therapeutic</font> <font color="blue">application</font> for     <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>Due to risks and <font color="blue">uncertainties</font> inherent in clinical testing and     the <font color="blue">regulatory</font> process, we are not able to estimate when <font color="blue">talabostat</font> may be     <font color="blue">commercially</font> available for any <font color="blue">application</font>, if at all</td>
    </tr>
    <tr>
      <td>In the US, we must obtain FDA approval for <font color="blue">talabostat</font> and <font color="blue">each <font color="blue">indication</font></font>     that we intend to <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">approval process</font> is typically     lengthy and expensive, and <font color="blue">such approval</font> is <font color="blue">never certain</font> and entails a high     degree of risk</td>
    </tr>
    <tr>
      <td>Products marketed, <font color="blue">manufacture</font>d or <font color="blue">distributed abroad</font> are     also subject to <font color="blue">foreign <font color="blue">government</font> regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Talabostat </font>has not received     <font color="blue"><font color="blue">regulatory</font> approval</font> to be <font color="blue">commercially</font> marketed and sold for any <font color="blue">therapeutic</font>     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, we will be unable to     market and sell <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict with certainty</font> if or when we     might  submit  <font color="blue">talabostat</font>  for <font color="blue"><font color="blue">regulatory</font> approval</font> for any <font color="blue">therapeutic</font>     <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Once we submit <font color="blue">talabostat</font> for review, we <font color="blue">cannot assure</font> you that     the FDA or other <font color="blue">regulatory</font> agencies will grant approvals on a <font color="blue">timely basis</font>     or  at all</td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">regulatory</font> approval</font> for any <font color="blue">therapeutic</font> <font color="blue">application</font> for     <font color="blue">talabostat</font> is delayed, our business, <font color="blue">financial condition</font> or results of     <font color="blue">operations</font> would be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Because we <font color="blue">rely on <font color="blue">third parties</font></font> to conduct <font color="blue">human clinical studies</font>, we may     <font color="blue">encounter delays</font> in product <font color="blue">development</font> and <font color="blue">commercialization</font>        We  have  <font color="blue">relatively few employees</font> and do not have <font color="blue">sufficient internal</font>     resources or experience to conduct human <font color="blue">clinical trials</font> completely on our     own</td>
    </tr>
    <tr>
      <td>We <font color="blue">must therefore contract with <font color="blue">third parties</font></font> to perform the clinical     trials needed for us to submit <font color="blue">talabostat</font> to the FDA for marketing approval</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  continue  to  increase our internal clinical <font color="blue">development</font>     <font color="blue">capability</font>, including our ability to supervise, manage and, <font color="blue">as <font color="blue">necessary</font></font>,     <font color="blue">replace outside vendors</font>, we <font color="blue">still outsource</font> a substantial amount of the     clinical trial <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td>Thus, we <font color="blue">may lose control over</font> the cost     of and time required to conduct these studies</td>
    </tr>
    <tr>
      <td>In addition, these third     <font color="blue">parties might</font> not conduct our <font color="blue">clinical trials</font> in accordance with <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The failure of any <font color="blue">contractor</font> to carry out its <font color="blue">contractual</font>     <font color="blue">duties could delay</font> or increase the cost of the successful <font color="blue">development</font> and     <font color="blue">commercialization</font> of <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>We may fail to <font color="blue">adequately</font> protect or enforce our <font color="blue">intellectual</font> property     rights,  and  our products and <font color="blue">processes may infringe</font> the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others        <font color="blue">Protection  </font>of our compounds and <font color="blue">technology</font> owned or <font color="blue">licensed by us</font> is     essential to our business</td>
    </tr>
    <tr>
      <td>Our policy is to protect our <font color="blue">technology</font> by, among     other  things,  filing  or  causing  to  be filed on our <font color="blue">behalf patent</font>     <font color="blue"><font color="blue">application</font>s</font> for <font color="blue">technology</font> relating to the <font color="blue">development</font> of our business</td>
    </tr>
    <tr>
      <td>We     own or have licensed 17 issued US patents and 16 pending US patent     <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>Most of these patents and patent <font color="blue"><font color="blue">application</font>s</font> relate to our     oncology,  diabetes  and  vaccine adjuvant <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font>     <font color="blue">extensions</font> are not taken into account, one US <font color="blue">patent expires</font> in 2007; one     US patent and one <font color="blue">application</font> expire in 2011; one US <font color="blue">patent expires</font> in     2012; and the <font color="blue">remaining patents</font> and <font color="blue"><font color="blue">application</font>s</font> expire in 2016 and beyond</td>
    </tr>
    <tr>
      <td>We  also  own or have <font color="blue">licensed foreign patents</font> and patent <font color="blue"><font color="blue">application</font>s</font>     <font color="blue">corresponding</font> to most of the US patents and patent <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>It is     possible that <font color="blue">no patents will</font> be issued on our pending patent <font color="blue"><font color="blue">application</font>s</font>,     and it is possible that our patent claims, now or in the future issued, will     not  be sufficient to protect our products and <font color="blue">technology</font>, will not be     sufficient to provide protection against <font color="blue">competitive</font> products, or otherwise     will not be <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patents issued</font> to or <font color="blue">licensed by us</font>     could  be  challenged,  invalidated,  infringed,  <font color="blue">circumvented</font> or held     unenforceable</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>Our  commercial  success  will  also  depend in part on our ability to     <font color="blue">commercialize</font> <font color="blue">talabostat</font> without infringing on patents or other <font color="blue">proprietary</font>     rights of others</td>
    </tr>
    <tr>
      <td><font color="blue">Talabostat </font>or our other drug <font color="blue">candidates</font> may infringe     current or future patents or other <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>To date, we     have not received any <font color="blue">communications from <font color="blue">third parties</font> nor</font> are we aware of     any claims <font color="blue">by <font color="blue">third parties</font></font> that our use of <font color="blue">talabostat</font> or any of our other     <font color="blue">activities</font> infringe upon the patent or other <font color="blue">proprietary</font> rights of any third     party</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you that other companies or <font color="blue">individuals</font>     have  not  or  will not <font color="blue">independently</font> develop <font color="blue"><font color="blue">substantially</font> equivalent</font>     <font color="blue">proprietary</font> rights or that other parties have not or will not be issued     patents that <font color="blue">may prevent</font> the sale of our products or require licensing and     the payment of <font color="blue"><font color="blue">significant</font> fees</font> or royalties in order for us to be able to     carry on our business</td>
    </tr>
    <tr>
      <td>If we are successful in the preclinical and clinical     <font color="blue">development</font> of PT-630, our <font color="blue">lead drug candidate</font> for the treatment of type 2     diabetes, to market and sell that drug we may need to obtain at least a     non-exclusive license for <font color="blue">relevant use patents from <font color="blue">third parties</font></font>, and there     can  be  no  assurance  that we will be able to obtain that <font color="blue">license on</font>     <font color="blue">economically</font> favorable terms, or at all</td>
    </tr>
    <tr>
      <td>We from time to time engage in     <font color="blue">discussions with</font> Tufts, other <font color="blue">licensors</font>, vendors and other <font color="blue">parties about</font> the     scope  and  <font color="blue">enforceability</font>  of our <font color="blue">contractual</font> rights that may include     <font color="blue">utilization</font>  of  <font color="blue">dispute resolution procedures contained</font> in applicable     <font color="blue">agreements</font></td>
    </tr>
    <tr>
      <td>Otherwise, we have not notified any <font color="blue">third party</font> that they are     infringing any of our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or other <font color="blue">legal proceedings could</font> result in substantial costs to     us and may be <font color="blue">necessary</font> to enforce any of our patents or other <font color="blue">proprietary</font>     rights or to determine the scope and validity or <font color="blue">enforceability</font> of other     parties’ <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">enforcement</font> of patent and     <font color="blue">intellectual</font> property claims are <font color="blue">both costly</font> and time consuming, even if the     <font color="blue">legal outcome</font> is favorable to us</td>
    </tr>
    <tr>
      <td>Any adverse <font color="blue">legal outcome</font> could subject us     to <font color="blue"><font color="blue">significant</font> liabilities</font> to <font color="blue">third parties</font>, require <font color="blue">disputed rights</font> to be     licensed from <font color="blue">third parties</font>, or require us to <font color="blue">cease <font color="blue">manufacturing</font></font> or selling     our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Our employees, consultants and advisors are required to <font color="blue">enter into written</font>     <font color="blue">confidential</font>ity  <font color="blue">agreements</font>  that  prohibit  the  <font color="blue">disclosure</font> or use of     <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>We also have entered into written <font color="blue">confidential</font>ity     <font color="blue">agreements</font>  that  are intended to protect our <font color="blue">confidential</font> information     delivered to <font color="blue">third parties</font> for research and other purposes</td>
    </tr>
    <tr>
      <td>However, these     <font color="blue">agreements</font> could be breached, and we may not have <font color="blue">adequate remedies</font> for any     breach, or our <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> information <font color="blue">could otherwise</font>     <font color="blue">become known</font> or be <font color="blue">independently</font> discovered by others</td>
    </tr>
    <tr>
      <td>We have not notified     any person of a violation of a <font color="blue">confidential</font>ity agreement that has <font color="blue">materially</font>     harmed our business</td>
    </tr>
    <tr>
      <td>If  our  <font color="blue"><font color="blue">competitor</font>s</font>  reach  the <font color="blue">market sooner</font> or develop products and     <font color="blue">technologies</font> that are more <font color="blue">effective</font>, less costly, or have reduced side     effects, our <font color="blue">commercial opportunity will</font> be reduced or eliminated        The <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industries are intensely <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">existing products on</font> the market, including generics, that are used     for  the  treatment of <font color="blue">subjects with</font> the same <font color="blue"><font color="blue">indication</font>s</font> that we have     targeted including, <font color="blue">among others</font>, Chiron’s Proleukin®, Bayer’s DTIC-Dome®,     Sanofi-Aventis’ Taxotere®, Bristol-Myers Squibb’s Paraplatin® and Platinol     AQ®,  AstraZeneca’s  Iressa®,  GSK’s  Bexxar®,  OSI Pharmaceutical’s /     Genentech’s Tarceva®, Eli Lilly’s Alimta® and Gemzar®, Genzyme’s / Berlex’s     Campath®, Biogen-IDEC’s Zevalin® and Roche / Genentech / Biogen-IDEC’s     Rituxan® / MabThera</td>
    </tr>
    <tr>
      <td>There are <font color="blue">also several</font> other potential <font color="blue">competitive</font>     novel  products in <font color="blue">development</font> at other <font color="blue">companies as well as currently</font>     <font color="blue">approved products</font> that are being developed for <font color="blue">additional</font> <font color="blue"><font color="blue">indication</font>s</font> that     may be <font color="blue">competitive</font> with our product’s <font color="blue"><font color="blue">indication</font>s</font> including, <font color="blue">among others</font>,     Genentech’s Avastin®, ImClone’s Erbitux®, Sanofi-Aventis’ Eloxatin®, and     Millennium’s  Velcade®</td>
    </tr>
    <tr>
      <td>If any of these products are successful in the     clinic, we may experience <font color="blue"><font color="blue">additional</font> competition</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">talabostat</font> is     still  in  clinical  <font color="blue">development</font>, we do not have the sales, marketing,     <font color="blue">manufacturing</font>  or  <font color="blue">distribution</font> capabilities <font color="blue">necessary</font> to <font color="blue">compete with</font>     well-established companies</td>
    </tr>
    <tr>
      <td>If <font color="blue">talabostat</font> is <font color="blue">approved by</font> the FDA for one or     more <font color="blue">therapeutic</font> <font color="blue"><font color="blue">application</font>s</font>, we may enter into <font color="blue">collaboration</font> <font color="blue">agreements</font>     with  one  or  more  established  companies in order to compete in the     marketplace</td>
    </tr>
    <tr>
      <td>There  can  be  no  assurances  that we would be able to     <font color="blue">successfully</font> enter into any such <font color="blue">collaboration</font>s with <font color="blue">third parties</font> or that     any such <font color="blue">collaboration</font>s would be <font color="blue">entered into on terms</font> satisfactory to us</td>
    </tr>
    <tr>
      <td>There  are  also  many  public  and  private <font color="blue">pharmaceutical</font> companies,     <font color="blue">bio<font color="blue">technology</font> companies</font>, public and private universities, <font color="blue">government</font>al     agencies and research <font color="blue">organizations</font> actively engaged in <font color="blue">drug discovery</font> and     research and <font color="blue">development</font> of products for the treatment of <font color="blue">subjects with</font> the     same <font color="blue"><font color="blue">indication</font>s</font> that we have                                           19     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>targeted</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">organizations</font> have financial, technical, <font color="blue">regulatory</font>,     patenting, <font color="blue">manufacturing</font> and marketing resources that are far greater than     ours</td>
    </tr>
    <tr>
      <td>If a <font color="blue">competitor</font> were to <font color="blue">successfully</font> develop or acquire rights to a     similar or more <font color="blue">effective</font> treatment of <font color="blue">subjects with</font> the same <font color="blue"><font color="blue">indication</font>s</font>     <font color="blue">targeted by us</font> or one that has reduced side effects or <font color="blue">offers <font color="blue">significant</font>ly</font>     lower  costs of treatment, or were to <font color="blue">successfully</font> enter the market in     advance of us with a similar or superior therapy, our business, financial     condition or results of <font color="blue">operations</font> could be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot provide</font> assurances that research and <font color="blue">development</font> by others will     not render our <font color="blue">technology</font> or <font color="blue">talabostat</font> obsolete or non-<font color="blue">competitive</font> or     result in <font color="blue">treatments</font> superior to any therapy or drug developed by us, or     that any drug or therapy developed by us will be preferred to any existing     or newly developed <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> strategy presents a number of risks        We do not currently have our own <font color="blue">manufacturing</font> facilities</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font>     outside <font color="blue">contractor</font>s for the <font color="blue">manufacture</font> of <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of our     clinical  trials  and the <font color="blue">commercialization</font> of <font color="blue">talabostat</font> will require     <font color="blue">sufficient access</font> to these external <font color="blue">manufacturing</font> capabilities</td>
    </tr>
    <tr>
      <td>Our outside <font color="blue">contractor</font>s may give greater priority to other products or for     other <font color="blue">reasons may fail</font> to <font color="blue">manufacture</font> or deliver the required supply of     <font color="blue">talabostat</font> in a cost-<font color="blue">effective</font> or <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Our current and future     <font color="blue">manufacture</font>rs  are and will be subject to <font color="blue">ongoing periodic unannounced</font>     <font color="blue">inspection by</font> the FDA and <font color="blue">corresponding</font> state and foreign agencies for     <font color="blue">compliance with</font> strictly enforced good <font color="blue">manufacturing</font> practice <font color="blue">regulations</font>     and similar state and foreign standards, and we do not have control over our     third-party <font color="blue">manufacture</font>rs’ <font color="blue">compliance with</font> these <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>Any  of  these  factors  could  in the future delay <font color="blue">clinical trials</font> or     <font color="blue">commercialization</font> of <font color="blue">talabostat</font>, interfere with sales, entail higher costs     or result in us being unable to <font color="blue">effective</font>ly sell our products</td>
    </tr>
    <tr>
      <td>To the extent     that we are reliant on a sole source of supply of a drug, any interruption     in  that  <font color="blue">supply could delay us</font> in <font color="blue">effective</font>ly developing, testing and     <font color="blue">commercializing</font> the drug</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">generate revenues</font> will</font> be diminished if <font color="blue">talabostat</font> is not     accepted in the marketplace, if we fail to obtain acceptable prices or if     <font color="blue">adequate <font color="blue">reimbursement</font></font> is not available for <font color="blue">talabostat</font> from third-party     payors        There are <font color="blue">competing products</font> to <font color="blue">talabostat</font> already in the market for the     treatment  of each <font color="blue">therapeutic</font> <font color="blue">indication</font> we are <font color="blue">currently pursuing</font> in     <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Even if approved for sale and <font color="blue">distribution</font> for one or more     <font color="blue"><font color="blue">therapeutic</font> <font color="blue"><font color="blue">indication</font>s</font></font>, <font color="blue">talabostat</font> might not achieve <font color="blue">market acceptance</font> for     such <font color="blue"><font color="blue">indication</font>s</font> or <font color="blue">remain on</font> the market</td>
    </tr>
    <tr>
      <td><font color="blue">Talabostat </font>may be <font color="blue">rejected by</font> the     <font color="blue">marketplace due</font> to many factors, including cost and the perceived risks     versus the benefits of <font color="blue">talabostat</font></td>
    </tr>
    <tr>
      <td>Physicians, subjects, payors or the     <font color="blue">medical community</font> in <font color="blue">general may</font> be unwilling to accept, prescribe, utilize,     recommend or reimburse for <font color="blue">talabostat</font> for such <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our drugs may be limited due to the continuing     efforts of <font color="blue">government</font> and third-party payors to contain or reduce the costs     of <font color="blue">health care through various</font> means</td>
    </tr>
    <tr>
      <td>For example, in many <font color="blue">markets outside</font>     the US, the pricing and <font color="blue">profitability</font> of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s are     subject  to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In the US, we expect that <font color="blue">there will</font>     continue  to  be  federal  and state proposals to implement <font color="blue">additional</font>     <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">recently enacted</font> Medicare Prescription     Drug, Improvement, and Modernization Act of 2003 provides a new <font color="blue">Medicare     </font><font color="blue">prescription</font> drug benefit beginning in 2006 and mandates other reforms</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  cannot  predict  the full <font color="blue">effects on</font> our business of the     <font color="blue">implementation</font> of this <font color="blue">new legislation</font>, it is possible that the new benefit     will result in <font color="blue">decreased <font color="blue">reimbursement</font></font> for <font color="blue">prescription</font> drugs which may     further exacerbate industry-wide pressure to reduce the <font color="blue">prices charged</font> for     <font color="blue">prescription</font> drugs</td>
    </tr>
    <tr>
      <td>This <font color="blue">could harm</font> our ability to market <font color="blue">talabostat</font> and     <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>Also, <font color="blue">increasing emphasis on managed care</font> in the US and the <font color="blue">possibility</font> of     <font color="blue">government</font> regulation of <font color="blue">prescription</font> drug prices will likely continue to     put <font color="blue">additional</font> pressure on the pricing of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>Cost <font color="blue">control initiatives could decrease</font> the price that we <font color="blue">might otherwise</font>     achieve for <font color="blue">talabostat</font> in the future</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">cost control initiatives</font>     <font color="blue">could <font color="blue">adversely affect</font></font> our ability to <font color="blue">commercialize</font> <font color="blue">talabostat</font> and our     ability to realize profits and <font color="blue">revenues from</font> this <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our  ability  to  <font color="blue">commercialize</font> <font color="blue">pharmaceutical</font> products, alone or with     <font color="blue">distributors</font>  or  others,  may  depend  in part on the extent to which     <font color="blue">reimbursement</font> for the <font color="blue">products will</font> be <font color="blue">available from</font>:           •   <font color="blue">government</font> and <font color="blue">health administration authorities</font>;           •   <font color="blue">private health insurers</font>; and           •   other third-party payors</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of newly     <font color="blue">approved healthcare products</font></td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare, are     <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td><font color="blue">Government     </font>and  other  third-party  payors increasingly are attempting to contain     healthcare costs by limiting both coverage and the level of <font color="blue">reimbursement</font>     for new drugs and by refusing, in some cases, to <font color="blue">provide coverage</font> for uses     of <font color="blue">approved products</font> for disease <font color="blue"><font color="blue">indication</font>s</font> for which the FDA has not     granted  labeling  approval</td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">insurance <font color="blue">coverage may</font></font> not be     available to subjects for any products we discover and develop, alone or     with our <font color="blue">strategic alliance partners</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">government</font> and other third-party     payors  do  not <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels for     <font color="blue">talabostat</font>, the <font color="blue">market acceptance</font> of these <font color="blue">products may</font> be reduced</td>
    </tr>
    <tr>
      <td>We use hazardous chemicals and <font color="blue">radioactive</font> and biological materials in our     business;  any disputes relating to improper use, handling, storage or     disposal of these <font color="blue">materials could</font> be time-consuming and costly        Our preclinical and clinical <font color="blue">operations</font> involve the use of <font color="blue">certain hazardous</font>     materials,  including <font color="blue">certain chemicals</font> and <font color="blue">radioactive</font> and biological     materials</td>
    </tr>
    <tr>
      <td>The  <font color="blue"><font color="blue">hazardous materials</font> used most frequently by us</font> in our     <font color="blue">operations</font>  include  sodium  chromate  containing chromium-51 (51 Cr),     nucleotides containing phosphorus-32 (32 P) and phenol</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> also     produce <font color="blue">hazardous waste products</font></td>
    </tr>
    <tr>
      <td>We are subject to the risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or discharge or any <font color="blue">resultant injury from</font> these materials, and     we do not maintain <font color="blue"><font color="blue">liability</font> insurance</font> for <font color="blue">contamination</font> or injury resulting     from the use of the materials</td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font>     govern  the  use, <font color="blue">manufacture</font>, storage, handling and disposal of these     materials</td>
    </tr>
    <tr>
      <td>We could be subject to damages, fines and penalties in the event     of an improper or <font color="blue">unauthorized release</font> of, or exposure of <font color="blue">individuals</font> to,     these <font color="blue">hazardous materials</font>, and our <font color="blue"><font color="blue">liability</font> could exceed</font> our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with <font color="blue">environmental laws</font></font> and <font color="blue">regulations</font> may be expensive, and     current or future environmental <font color="blue">regulations</font> may impair our business</td>
    </tr>
    <tr>
      <td>To     date,  our  compliance  costs  with  respect to <font color="blue">environmental laws</font> and     <font color="blue">regulations</font> have <font color="blue">been minimal</font></td>
    </tr>
    <tr>
      <td>We may be sued for product or <font color="blue">operational <font color="blue">liability</font></font>        We may be held liable if any of our products or <font color="blue">operations</font> cause injury or     death  or  are  found  otherwise  unsuitable  during  <font color="blue">product testing</font>,     <font color="blue">manufacturing</font>, marketing or sale</td>
    </tr>
    <tr>
      <td>We currently maintain a dlra2 million general     <font color="blue">liability</font>  policy  and a dlra5 million annual aggregate product <font color="blue">liability</font>     insurance related to our <font color="blue">clinical trials</font> consistent with industry standards</td>
    </tr>
    <tr>
      <td>When <font color="blue">necessary</font> for our products, we intend to obtain <font color="blue">additional</font> product     <font color="blue"><font color="blue">liability</font> insurance</font></td>
    </tr>
    <tr>
      <td>Insurance <font color="blue">coverage may</font> be prohibitively expensive, may     not <font color="blue">fully cover</font> our <font color="blue">potential liabilities</font> or may not be available in the     future</td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>to obtain sufficient insurance coverage at an acceptable     cost or otherwise to <font color="blue">protect against</font> potential product <font color="blue">liability</font> claims     could prevent or inhibit the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>If we are     sued for any injury caused by our products, the <font color="blue">litigation could consume</font>     substantial time and attention of our <font color="blue">management</font> and our <font color="blue">liability</font> could     exceed our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose key personnel</font> or are unable to attract or retain <font color="blue">additional</font>     personnel,   we  may  be  unable  to  develop  <font color="blue">talabostat</font>  or  achieve     <font color="blue">commercialization</font> <font color="blue">objectives</font>        We are highly <font color="blue">dependent on</font> Donald R Kiepert, Jr, our Chairman, President     and Chief Executive Officer, Richard N Small, our Senior Vice President,     Chief Financial Officer and Treasurer, Margaret J Uprichard, our                                           21     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>Senior Vice President and Chief Development Officer, Michael P Duffy, our     Senior Vice President, General Counsel and Secretary, Barry Jones, our     Senior Vice President for Research, as well as other key members of our     <font color="blue">management</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>To date, we have not maintained key-man     <font color="blue"><font color="blue">liability</font> insurance</font> to <font color="blue">protect against</font> the loss of any of these personnel,     with the exception of Mr</td>
    </tr>
    <tr>
      <td>Kiepert, for whom we maintain a key-man <font color="blue">liability</font>     insurance policy</td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">personnel may</font> have a <font color="blue">disruptive</font>     effect on our <font color="blue">operations</font> until they are replaced, and may have a material     adverse effect on our product <font color="blue">development</font> and <font color="blue">commercialization</font> efforts if     we are not able to <font color="blue">attract qualified replacements</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our <font color="blue">continued ability</font> to attract, retain and motivate     highly qualified <font color="blue">management</font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>In particular, our     preclinical and clinical <font color="blue">operations</font> <font color="blue">depend on</font> our ability to attract and     retain <font color="blue">highly skilled scientists</font> and clinical <font color="blue">development</font> and <font color="blue">regulatory</font>     <font color="blue">affairs personnel</font></td>
    </tr>
    <tr>
      <td>In addition, we will need to hire <font color="blue">additional</font> personnel     and  develop  <font color="blue">additional</font>  <font color="blue">collaboration</font>s  as we continue to expand our     preclinical and clinical <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We are not aware of any <font color="blue">key employee</font>     who plans to retire or terminate his or her <font color="blue">employment with us</font> in the near     future</td>
    </tr>
    <tr>
      <td>Despite our ability in the past in attracting and retaining key     personnel, we <font color="blue">cannot provide</font> assurances that we will be able to continue to     attract, retain or <font color="blue">motivate personnel</font> or develop or maintain <font color="blue">such outside</font>     <font color="blue">relationships</font> in the future</td>
    </tr>
    <tr>
      <td>We have <font color="blue">contingent liabilities</font> relating to our historical <font color="blue">discontinue</font>d     <font color="blue">operations</font> that <font color="blue">could give rise</font> to <font color="blue">liability</font> risks in the future        Prior to the sale of <font color="blue">substantially</font> all of our non-cash assets to Whatman in     May of 2001, we were engaged in the business of developing and supplying     <font color="blue"><font color="blue">blood filtration</font> devices</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although Whatman </font><font color="blue">contractual</font>ly assumed and agreed     to indemnify us and hold <font color="blue">us harmless from</font> and <font color="blue">against most liabilities</font> and     <font color="blue">obligation</font>s arising out of the conduct of our <font color="blue">blood filtration</font> business, we     retained <font color="blue">certain known</font> and <font color="blue">unknown risks</font> that were not <font color="blue">contractual</font>ly assumed     by Whatman including <font color="blue">without limitation</font>, (i) any of our <font color="blue">liabilities under</font>     any benefit plan, (ii) tax liabilities incurred which relate to periods     prior to the closing of the Whatman <font color="blue">transaction</font>, (iii) accounts payable     arising prior to the closing of the Whatman <font color="blue">transaction</font>, (iv) any of our     <font color="blue">liabilities which</font> were owed to our <font color="blue">security holders</font> in their <font color="blue">capacity as</font>     such, and (v) our <font color="blue">liabilities which</font> were owed to Sepracor, Inc</td>
    </tr>
    <tr>
      <td>arising or     resulting from its respective <font color="blue">contractual</font> <font color="blue">relationships</font> with us</td>
    </tr>
    <tr>
      <td>If for any     reason Whatman, or its <font color="blue">successors</font>, is not able to satisfy any of the assumed     liabilities, such outcome could have a material and adverse effect on our     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Accordingly, there can be <font color="blue">no assurances</font> that claims     arising out of our historical business and <font color="blue">operations</font> would not be asserted     <font color="blue">against us</font> in the future and, if asserted, there can be <font color="blue">no assurances</font> that     we <font color="blue">would prevail</font></td>
    </tr>
    <tr>
      <td>If we are unable to maintain <font color="blue">compliance with</font> NASDAQ listing <font color="blue">requirements</font>,     our <font color="blue">stock could</font> be delisted, and the <font color="blue">trading price</font>, volume and <font color="blue">marketability</font>     of our <font color="blue">stock could</font> be <font color="blue"><font color="blue">adversely affect</font>ed</font>        <font color="blue">As of April </font>2, 2004, our <font color="blue"><font color="blue">common stock</font> began trading on</font> the NASDAQ Capital     Market</td>
    </tr>
    <tr>
      <td>Previously, our <font color="blue">common stock</font> was traded on the <font color="blue">OTC Bulletin Board</font></td>
    </tr>
    <tr>
      <td>There  can be <font color="blue">no assurances</font>, however, that we will be able to maintain     <font color="blue">compliance with</font> NASDAQ’s <font color="blue">present listing standards</font>, or that NASDAQ will not     implement <font color="blue">additional</font> listing standards with which we will be unable to     comply</td>
    </tr>
    <tr>
      <td>Failure to maintain <font color="blue">compliance with</font> NASDAQ listing <font color="blue">requirements</font>     could result in the delisting of our <font color="blue">shares from trading on</font> the <font color="blue">NASDAQ     </font>system, <font color="blue">which could</font> have a material adverse effect on the <font color="blue">trading price</font>,     volume and <font color="blue">marketability</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">subsequent sale</font> of a substantial number of shares of our <font color="blue">common stock</font>     could  cause  our stock price to decline and cause our <font color="blue">stockholders</font> to     experience substantial dilution        In  total,  <font color="blue">certain entities</font> and <font color="blue">individuals</font> hold <font color="blue">existing warrants</font> to     <font color="blue">purchase up</font> to 2cmam592cmam500 shares of our <font color="blue">common stock</font> at a <font color="blue">weighted average</font>     <font color="blue">exercise price</font> of dlra3dtta78 as of March 6, 2006</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">certain entities</font>     and <font color="blue">individuals</font> hold <font color="blue">existing options</font> to purchase 4cmam343cmam103 shares of our     common  stock  at an average <font color="blue">exercise price</font> of dlra3dtta85</td>
    </tr>
    <tr>
      <td>The exercise and     <font color="blue">subsequent sale</font> of a substantial amount of these warrants and <font color="blue">options could</font>     <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>To the extent we     raise <font color="blue">additional</font> capital by issuing <font color="blue">equity securities</font>, all <font color="blue">stockholders</font> may     experience substantial dilution</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>Our <font color="blue">stock price could</font> be volatile and our <font color="blue">trading volume may fluctuate</font>     <font color="blue">substantially</font>        The price of our <font color="blue">common stock</font> has been and may in the <font color="blue">future continue</font> to be     extremely volatile, with the <font color="blue">sale price fluctuating from</font> a low of dlra2dtta72 to a     high of dlra6dtta95 in the two-year period ended March 3, 2006</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors could</font>     have  a  <font color="blue">significant</font>  impact  on the <font color="blue">future price</font> of our <font color="blue">common stock</font>,     including:           •   progress or results of any of our <font color="blue">clinical trials</font>, in particular any     <font color="blue">announcements</font> regarding the progress or results of our <font color="blue">clinical trials</font> for     <font color="blue">talabostat</font>;           •   progress of <font color="blue"><font color="blue">regulatory</font> approval</font> of our <font color="blue">product candidate</font>, <font color="blue">talabostat</font>,     and <font color="blue">compliance with</font> ongoing <font color="blue">regulatory</font> <font color="blue">requirements</font>;           •   our ability to establish <font color="blue">collaboration</font>s for the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our <font color="blue"><font color="blue">product candidate</font>s</font>;           •   <font color="blue">market acceptance</font> of our <font color="blue"><font color="blue">product candidate</font>s</font>;           •   our ability to raise <font color="blue">additional</font> capital to fund our <font color="blue">operations</font>,     <font color="blue">whether through</font> the issuance of <font color="blue">equity securities</font> or debt;           •   technological innovations, new <font color="blue">commercial products</font> or <font color="blue">drug discovery</font>     efforts and preclinical and clinical <font color="blue">activities</font> by us or our <font color="blue"><font color="blue">competitor</font>s</font>;           •   changes in our <font color="blue">intellectual</font> property portfolio or <font color="blue"><font color="blue">development</font>s</font> or     <font color="blue">disputes concerning</font> the <font color="blue">proprietary</font> rights of our <font color="blue"><font color="blue">product candidate</font>s</font>;           •   our ability to obtain component materials and <font color="blue">successfully</font> enter into     and maintain <font color="blue">manufacturing</font> <font color="blue">relationships</font> for our <font color="blue"><font color="blue">product candidate</font>s</font>;           •   our ability to form <font color="blue">strategic partnerships</font> or <font color="blue">joint ventures</font>;           •   maintenance of our <font color="blue">existing licensing agreement with</font> Tufts University;           •   changes in <font color="blue">government</font> <font color="blue">regulations</font>;           •   issuance of new or changed <font color="blue">securities analysts</font>’ reports or     <font color="blue">recommendations</font>;           •   <font color="blue">general economic conditions</font> and other <font color="blue">external factors</font>;           •   actual or anticipated <font color="blue">fluctuations</font> in our <font color="blue">quarterly financial</font> and     operating results; and           •   degree of <font color="blue">trading liquidity</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has from time to time experienced extreme     price  and volume <font color="blue">fluctuations</font> which may be unrelated to the operating     performance  of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>For the three-month period ended     March 3, 2006, the <font color="blue">daily trading volume</font> for shares of our <font color="blue">common stock</font>     ranged from 4cmam200 to 1cmam051cmam700 shares traded per day, and the <font color="blue">average daily</font>     trading volume during such three-month period was only 114cmam989 shares traded     per day</td>
    </tr>
    <tr>
      <td>Accordingly, our investors who wish to dispose of their shares of     <font color="blue">common stock</font> on any <font color="blue">given trading day may</font> not be able to do so or may be     able to dispose of only a portion of their shares of <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>